Posted by PeterMartin on May 7, 2018, at 15:51:26
I'd be interested in trying this although I'm sure it'll be extremely expensive whenever available. Article: https://www.empr.com/news/esketamine-nasal-spray-treatment-resistant-depression-elderly/article/763942/
Phase 3:
-
Positive Results Announced for Esketamine in Treatment-Resistant DepressionFirst-of-its-kind study conducted in elderly patients with treatment-resistant depression
First-of-its-kind study conducted in elderly patients with treatment-resistant depression
Janssen announced positive results from two Phase 3 studies evaluating esketamine nasal spray in patients with treatment-resistant depression (defined as patients who have not responded to ≥2 antidepressants of adequate dose and duration in the current episode of depression). In both studies, the primary efficacy endpoint was change from baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.In a study evaluating adults with treatment-resistant depression (N=223), flexibly dosed esketamine nasal spray (56mg or 84mg) added to a newly initiated oral antidepressant was associated with a statistically significant, clinically meaningful rapid reduction of depressive symptoms vs placebo nasal spray plus a newly initiated oral antidepressant (least squares [LS] mean difference -4.0, 95% CI: -7.31, -0.64; P =.010).
A second study in elderly patients (≥65 years) with treatment-resistant depression (N=138) found that flexibly dosed esketamine nasal spray (28mg, 56mg or 84mg) added to a newly initiated oral antidepressant led to clinically meaningful effects vs placebo nasal spray plus a newly initiated oral antidepressant (median unbiased estimate of difference from placebo -3.6, 95% CI: -7.20, 0.07; P =.029), however, the study did not reach statistical significance for its primary efficacy endpoint.
poster:PeterMartin
thread:1098583
URL: http://www.dr-bob.org/babble/20180331/msgs/1098583.html